CytomX Therapeutics is shifting its focus to preclinical and early clinical studies, emphasizing alliances and slashing its workforce by about 40% to extend cash flow to 2025.
CureVac has filed a lawsuit against BioNTech and two of its subsidiaries for allegedly infringing on its intellectual property rights over mRNA technology used in the COVID-19 vaccine.
The Phase II study, conducted in the Netherlands, evaluated the single-dose ANEB-001 in treating healthy participants affected by THC. Anebulo plans to file an IND with the FDA by the end of 2022.
The transaction, expected to close in the third quarter of this year, includes TeneoTwo’s proposed drug for relapsed and refractory B-cell non-Hodgkin lymphoma TNB-486.
Hyloris did not provide details on the FDA’s concern regarding Maxigesic IV but said it will fully comply with whatever is necessary to move the product forward.
Cellectis shared how its novel immune-evasive universal CAR T cells may potentially deploy large amounts of T-cell product candidates to target multiple malignancies.
The FDA’s decision came after researchers found cases of drug-induced liver injury in some patients. Tolebrutinib is being evaluated for relapsing types of MS, MG, nrSPMS, and PPMS.
Icosavax posted positive topline interim data from its Phase I/Ib trial of IVX-121, its candidate virus-like particle vaccine against the respiratory syncytial virus in young and older adults.
The Phase III study of Jazz Pharmaceuticals cannabis-derived MS Sativex failed to achieve the primary endpoint of an improvement in muscle tone in patients.
Ascletis has commenced its Phase II trial in China for its candidate drug ASC22 alongside anti-retroviral therapy for the functional cure and immune restoration of HIV-1 infection.
